8-K Announcements
6Material company update
Mar 27, 2026·SEC
Material company update
Mar 2, 2026·SEC
Material company update
Nov 13, 2025·SEC
Monopar Therapeutics Inc.(MNPR)Earnings, Financials & Key Ratios
MNPR•NASDAQ
$63.86
$425M mkt cap·Price updated May 6, 2026
AboutMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.Show more
- Revenue$0
- EBITDA-$16M-83.0%
- Net Income-$16M-85.5%
- EPS (Diluted)-1.36-134.5%
- ROE-51.42%+52.0%
- ROIC-321.43%+94.3%
MNPR Key Insights
Monopar Therapeutics Inc. (MNPR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 20.9% through buybacks
✗Weaknesses
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 13.3x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MNPR Price & Volume
Monopar Therapeutics Inc. (MNPR) stock price & volume — 10-year historical chart
Loading chart...
MNPR Growth Metrics
Monopar Therapeutics Inc. (MNPR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-200.27%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-350%
Return on Capital
10 Years-75.7%
5 Years-67.43%
3 Years-79.5%
Last Year-53.32%
MNPR Recent Earnings
Monopar Therapeutics Inc. (MNPR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)
Q2 2026Latest
Mar 27, 2026EPS
$0.61
Est $0.51
-19.1%
Revenue
—
Q4 2025
Nov 13, 2025EPS
$0.48
Est $0.46
-4.3%
Revenue
—
Q3 2025
Aug 12, 2025EPS
$0.35
Est $0.47
+25.5%
Revenue
—
Q2 2025
May 13, 2025EPS
$0.38
Est $0.65
+41.5%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 27, 2026 | $0.61vs $0.51-19.1% | — |
| Q4 2025 | Nov 13, 2025 | $0.48vs $0.46-4.3% | — |
| Q3 2025 | Aug 12, 2025 | $0.35vs $0.47+25.5% | — |
| Q2 2025 | May 13, 2025 | $0.38vs $0.65+41.5% | — |
Based on last 12 quarters of dataView full earnings history →
MNPR Peer Comparison
Monopar Therapeutics Inc. (MNPR) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CLDX | 2.29B | 34.39 | -8.82 | -78.63% | -172.53% | -49.09% | 0.00 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 TPVG | 225.54M | 5.57 | 4.57 | 36.55% | 13.09% | 1.33 | ||
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 ADXN | 4.52M | 6.85 | 0.64 | -74.95% | -90.18% | -78.31% | 0.00 | |
 CASI | 2.33M | 0.15 | -0.06 | -15.77% | -183.93% | -301.8% | 11.96 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 SNDX | 1.82B | 20.65 | -6.28 | 6.28% | -112.01% | -256.66% | 5.36 |
Compare MNPR vs Peers
Monopar Therapeutics Inc. (MNPR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MNPR Income Statement
Monopar Therapeutics Inc. (MNPR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 1.19M | 16.6M | 3.4M | 4.32M | 6.51M | 9.13M | 10.54M | 8.83M | 16.16M | 21.62M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 912.47K | 1.17M | 1.63M | 2.36M | 2.44M | 2.63M | 2.95M | 3.23M | 3.16M | 5.74M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 280.36K | 935.32K | 1.77M | 1.97M | 4.07M | 6.49M | 7.59M | 5.6M | 13.01M | 15.89M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 14.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -1.19M▲ 0% | -16.6M▼ 1291.9% | -3.4M▲ 79.5% | -4.32M▼ 27.1% | -6.51M▼ 50.5% | -9.13M▼ 40.2% | -10.54M▼ 15.4% | -8.83M▲ 16.2% | -16.16M▼ 83.0% | -21.62M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -73.12% | -1291.9% | 79.5% | -27.06% | -50.54% | -40.23% | -15.44% | 16.19% | -83.01% | - |
| EBITDA | 0 | -14.5M | -72K | -4.22M | 0 | -9.13M | -10.54M | -8.83M | -16.16M | -20.04M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 100% | - | 99.5% | -5767.88% | 100% | - | -15.44% | 16.19% | -83.01% | -316.04% |
| D&A (Non-Cash Add-back) | 1.19M | 2.1M | 3.33M | 0 | 6.51M | 0 | 0 | 0 | 0 | 0 |
| EBIT | -1.18M | -16.55M | -3.33M | -4.22M | -6.51M | -9.13M | -10.54M | -8.83M | -16.16M | -20.04M |
| Net Interest Income | 0 | 0 | 0 | 98.89K | 81.9K | 24.02K | 21.24K | 429.04K | 404.02K | 657M |
| Interest Income | 7.23K | 48.26K | 103.22K | 98.89K | 81.9K | 24.02K | 21.24K | 429.04K | 404.02K | 657M |
| Interest Expense | 7.23K | 48.26K | 103.22K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 7.23K | 48.26K | 31.15K | 98.89K | 204.3K | 24.02K | 21.24K | 429.04K | 575.3K | 2.18M |
| Pretax Income | -1.18M▲ 0% | -16.55M▼ 1297.3% | -3.3M▲ 80.1% | -4.22M▼ 28.0% | -6.3M▼ 49.2% | -9.1M▼ 44.4% | -10.52M▼ 15.5% | -8.4M▲ 20.1% | -15.59M▼ 85.5% | -19.44M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 800 | 0 | -71.61K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.07% | 0% | 2.17% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -1.19M▲ 0% | -16.55M▼ 1296.3% | -3.23M▲ 80.5% | -4.22M▼ 30.9% | -6.3M▼ 49.2% | -9.1M▼ 44.4% | -10.52M▼ 15.5% | -8.4M▲ 20.1% | -15.59M▼ 85.5% | -19.44M▲ 0% |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -72.58% | -1296.34% | 80.5% | -30.88% | -49.23% | -44.39% | -15.52% | 20.1% | -85.5% | -200.27% |
| Net Income (Continuing) | -1.19M | -16.55M | -3.23M | -4.22M | -6.3M | -9.1M | -10.52M | -8.4M | -15.59M | -19.44M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.12▲ 0% | -1.59▼ 1225.0% | -0.31▲ 80.5% | -0.40▼ 29.0% | -0.58▼ 45.0% | -0.73▼ 25.9% | -0.83▼ 13.7% | -0.58▲ 30.1% | -1.36▼ 134.5% | -2.73▲ 0% |
| EPS Growth % | -42.52% | -1225% | 80.5% | -29.03% | -45% | -25.86% | -13.7% | 30.12% | -134.48% | -350% |
| EPS (Basic) | -0.12 | -1.59 | -0.31 | -0.40 | -0.58 | -0.73 | -0.83 | -0.58 | -1.36 | - |
| Diluted Shares Outstanding | 9.86M | 10.42M | 10.42M | 10.59M | 10.96M | 12.47M | 12.72M | 14.51M | 11.48M | 7.12M |
| Basic Shares Outstanding | 9.85M | 10.42M | 10.42M | 10.59M | 10.96M | 12.47M | 12.72M | 14.51M | 11.44M | 7.12M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MNPR Balance Sheet
Monopar Therapeutics Inc. (MNPR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.1M | 9.13M | 7.32M | 13.23M | 16.8M | 20.52M | 13.17M | 7.33M | 60.29M | 144.09M |
| Cash & Short-Term Investments | 2.07M | 8.98M | 6.89M | 13.21M | 16.74M | 20.3M | 13.12M | 7.27M | 60.21M | 143.68M |
| Cash Only | 2.07M | 8.98M | 6.89M | 13.21M | 16.74M | 20.3M | 8.19M | 7.27M | 45.82M | 127.68M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 4.93M | 0 | 14.4M | 16M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 15.71K | 62.69K | 217.75K | 45.98K | 66.43K | 78.87K | 415K |
| Total Non-Current Assets | 800.39K | 800.03K | 410.67K | 122.38K | 68.86K | 0 | 61.23K | 12.65K | 0 | 107K |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 61.23K | 12.65K | 0 | 106.67K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 730.65M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 800.39K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | -729.85M | 410.67K | 122.38K | 68.86K | 0 | 0 | 0 | 0 | 334 |
| Total Assets | 2.9M▲ 0% | 9.93M▲ 243.0% | 7.32M▼ 26.3% | 13.35M▲ 82.5% | 16.87M▲ 26.3% | 20.52M▲ 21.7% | 13.23M▼ 35.5% | 7.35M▼ 44.5% | 60.29M▲ 720.8% | 144.2M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
| Asset Growth % | 2.39% | 242.98% | -26.31% | 82.46% | 26.34% | 21.66% | -35.55% | -44.47% | 720.83% | 4164.86% |
| Total Current Liabilities | 64.51K | 311.87K | 399.55K | 724.16K | 1.18M | 1.58M | 3.13M | 1.76M | 5.25M | 2.57M |
| Accounts Payable | 64.51K | 311.87K | 399.55K | 724.16K | 1.18M | 1.58M | 3.13M | 1.76M | 2.25M | 2.54M |
| Days Payables Outstanding | - | - | - | - | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 32.48x | 29.28x | 18.32x | 18.27x | 14.28x | 12.98x | 4.21x | 4.17x | 11.47x | 11.47x |
| Quick Ratio | 32.48x | 29.28x | 18.32x | 18.27x | 14.28x | 12.98x | 4.21x | 4.17x | 11.47x | 11.47x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 8.41K | 0 | 0 | 71.45K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 8.41K | 0 | 0 | 151.25K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 570 |
| Total Liabilities | 64.51K | 311.87K | 399.55K | 724.16K | 1.18M | 1.58M | 3.14M | 1.76M | 5.25M | 2.64M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 8.41K | 0 | 0 | 102.24K |
| Net Debt | -2.07M | -8.98M | -6.89M | -13.21M | -16.74M | -20.3M | -8.18M | -7.27M | -45.82M | -127.57M |
| Debt / Equity | - | - | - | - | - | - | 0.00x | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.01x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 6.37x |
| Interest Coverage | -164.94x | -344.07x | -32.97x | - | - | - | - | - | - | - |
| Total Equity | 2.83M▲ 0% | 9.62M▲ 239.8% | 6.92M▼ 28.1% | 12.63M▲ 82.5% | 15.69M▲ 24.3% | 18.94M▲ 20.7% | 10.09M▼ 46.7% | 5.59M▼ 44.6% | 55.04M▲ 885.0% | 141.56M▲ 0% |
| Equity Growth % | 2.79% | 239.78% | -28.08% | 82.53% | 24.26% | 20.71% | -46.73% | -44.62% | 884.95% | 5020.44% |
| Book Value per Share | 0.29 | 0.92 | 0.66 | 1.19 | 1.43 | 1.52 | 0.79 | 0.39 | 4.79 | 19.87 |
| Total Shareholders' Equity | 2.83M | 9.62M | 6.92M | 12.63M | 15.69M | 18.94M | 10.09M | 5.59M | 55.04M | 141.56M |
| Common Stock | 0 | 9.29K | 9.29K | 10.59K | 11.45K | 12.6K | 12.95K | 14.9K | 6.1K | 6.66K |
| Retained Earnings | -1.87M | -18.43M | -21.66M | -25.88M | -32.19M | -41.29M | -51.8M | -60.21M | -75.79M | -84.31M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -2.4K | -10.97K | -7.87K | -3.16K | 8.94K | -14.13K | 35.99K | 11.7K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MNPR Cash Flow Statement
Monopar Therapeutics Inc. (MNPR) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -1.19M | -2.63M | -2.89M | -3.02M | -4.66M | -7.32M | -7.23M | -7.86M | -6.4M | -6.4M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -87.74% | -119.94% | -9.87% | -4.54% | -54.5% | -56.95% | 1.21% | -8.71% | 18.5% | -330.37% |
| Net Income | -1.19M | -16.55M | -3.23M | -4.22M | -6.3M | -9.1M | -10.52M | -8.4M | -15.59M | -19.44M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 305.2K | 529.33K | 1.01M | 1.32M | 1.47M | 1.64M | 1.9M | 1.14M | 4.01M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 9.33K | 13.5M | 441.65K | 0 | -122.4K | 0 | 0 | 0 | 4.55M | 4.55M |
| Working Capital Changes | -9.04K | 120.58K | -188.16K | 196.02K | 443.81K | 317.77K | 1.65M | -1.35M | 3.49M | 47.43K |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -9.33K | 247.36K | 87.68K | 243.53K | 447.6K | 403.97K | 1.48M | -1.33M | 506.79K | 784.62K |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 | -4.92M | 4.93M | -14.34M | -15.6M |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 1.26M | 9.54M | -206.27K | 9.35M | 8.18M | 10.88M | 32.87K | 2.03M | 59.29M | 148.1M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 122.4K | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 0 | 1000K | 1000K | 1000K | 109.34K | 1000K | 1000K | 2.02M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -35M |
| Other Financing | 0 | 4.83M | -206.27K | -874.81K | -115.57K | -45.77K | -76.46K | -46.97K | -104.14K | -901.19K |
| Net Change in Cash | 67.87K▲ 0% | 6.91M▲ 10079.9% | -2.89M▼ 141.8% | 6.32M▲ 318.8% | 3.52M▼ 44.3% | 3.57M▲ 1.2% | -12.12M▼ 439.7% | -920.11K▲ 92.4% | 38.55M▲ 4289.7% | 121.66M▲ 0% |
| Free Cash Flow | -1.19M▲ 0% | -2.63M▼ 119.9% | -2.89M▼ 9.9% | -3.02M▼ 4.5% | -4.66M▼ 54.5% | -7.32M▼ 56.9% | -7.23M▲ 1.2% | -7.86M▼ 8.7% | -6.4M▲ 18.5% | -10.83M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -87.74% | -119.94% | -9.87% | -4.54% | -54.5% | -56.95% | 1.21% | -8.71% | 18.5% | -81.96% |
| FCF per Share | -0.12 | -0.25 | -0.28 | -0.29 | -0.43 | -0.59 | -0.57 | -0.54 | -0.56 | -0.56 |
| FCF Conversion (FCF/Net Income) | 1.01x | 0.16x | 0.89x | 0.71x | 0.74x | 0.80x | 0.69x | 0.94x | 0.41x | 0.56x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MNPR Key Ratios
Monopar Therapeutics Inc. (MNPR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -42.45% | -265.93% | -39.04% | -43.23% | -44.52% | -52.57% | -72.44% | -107.19% | -51.42% | -25.72% |
| Return on Invested Capital (ROIC) | -118.69% | -1784.05% | -769.75% | - | - | - | -2878.57% | -5671.91% | -321.43% | -321.43% |
| Debt / Equity | - | - | - | - | - | - | 0.00x | - | - | 0.00x |
| Interest Coverage | -164.94x | -344.07x | -32.97x | - | - | - | - | - | - | - |
| FCF Conversion | 1.01x | 0.16x | 0.89x | 0.71x | 0.74x | 0.80x | 0.69x | 0.94x | 0.41x | 0.56x |
MNPR SEC Filings & Documents
Monopar Therapeutics Inc. (MNPR) SEC filings — annual & quarterly reports (10-K, 10-Q)
MNPR Frequently Asked Questions
Monopar Therapeutics Inc. (MNPR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Monopar Therapeutics Inc. (MNPR) grew revenue by 0.0% over the past year. Growth has been modest.
Monopar Therapeutics Inc. (MNPR) reported a net loss of $19.4M for fiscal year 2024.
Dividend & Returns
Monopar Therapeutics Inc. (MNPR) has a return on equity (ROE) of -51.4%. Negative ROE indicates the company is unprofitable.
Monopar Therapeutics Inc. (MNPR) had negative free cash flow of $10.8M in fiscal year 2024, likely due to heavy capital investments.
Explore More MNPR
Monopar Therapeutics Inc. (MNPR) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates